Jagsonpal Pharma

Jagsonpal Pharmaceuticals announced it had entered into a definitive agreement to acquire an 85% stake in Mumbai-based Aequitas Healthcare Private Limited, a hospital-focused pharmaceutical distributor. The transaction was valued at ₹20.8 crore in cash and marked Jagsonpal's strategic entry into the hospital segment. Aequitas, founded in 2017, generated revenues of ₹53.31 crore in fiscal 2026 and serves leading hospital chains across India. Jagsonpal's managing director Manish Gupta said the deal provides a ready platform to expand its branded product portfolio through institutional channels. The acquisition will be funded entirely from internal accruals and is expected to close by July 15, 2026. The existing directors of Aequitas will retain a 15% stake and continue to be associated with the business. The transaction requires no regulatory approvals and is not a related-party deal.

Powered by Tijori

April 27 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - BUY-BACK RESOLUTION PASSED WITH 99.99% VOTES IN FAVOUR

Source text: ID:nNSE5r8rkF

Further company coverage: JGSN.NS

(([email protected];;))

March 13 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• GOT ORDER FOR TAX DEMAND OF 48.2 MILLION RUPEES

Source text: ID:nBSE6y3GBF

Further company coverage: JGSN.NS

(([email protected];;))

** Shares of Jagsonpal Pharmaceuticals JGSN.NS rise 8.9% to 195.16 rupees, set to gain for third straight session

** Pharmaceuticals co to buyback up to 1.6 mln shares for 400 mln rupees ($4.3 mln) at 250 rupees per share, 39.5% premium to closing price on Wednesday

** Trading vols over 10x the 30-day average at 1.3 mln shares so far

** JGSN up ~1% YTD

($1 = 92.0910 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

** Jagsonpal Pharmaceuticals JGSN.NS rises 7.9% to 181.50 rupees

** Co's board to meet on March 12 to consider share buyback

** Trading vols at more than 26x the 30-day average in stock's busiest session since July 28, 2025

** JGSN down 5.8% YTD

(Reporting by Vijay Malkar)

(([email protected];))

March 9 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• BOARD TO CONSIDER SHARE BUYBACK ON MARCH 12, 2026

Source text: ID:nBSE4P0Zv8

Further company coverage: JGSN.NS

(([email protected];;))

**Shares of Jagsonpal Pharmaceuticals JGSN.NS fall for sixth straight session; down 4.6% to 156.9 rupees

**Drugmaker's Q3 net profit slumps 66% to 109.5 million rupees; Q3 revenue falls 1.5% to 729.5 million rupees

**Co recorded a 20.8 million rupees charge after India notified new labour codes, the country's biggest overhaul of workers' laws in decades

**More than 54,854 shares change hands vs 30 day avg of 42,597 shares

**Stock fell 21.2% in 2025

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

Dec 30 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• RECEIVES TAX DEMAND ORDER TOTALING 15.2 MILLION RUPEES

Source text: ID:nBSE18JFkx

Further company coverage: JGSN.NS

(([email protected];))

April 2 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• CUSTOMS AUTHORITY PASSES ORDER ON JAGSONPAL PHARMACEUTICALS

• ORDER CONFIRMS DIFFERENTIAL DUTY OF 51 MILLION RUPEES PLUS PENALTY

Source text: ID:nBSE6sHSXM

Further company coverage: JGSN.NS

(([email protected];;))

** Shares of Jagsonpal Pharmaceuticals JGSN.NS slide as much 4.4% to 210.03 rupees, last down 1.1%

** Drugmaker gets U.S. FDA warning letter related to drug listing, establishment registration after plant inspection

** Co estimates sales hit worth 35 mln rupees ($403,960) so far in current fiscal year

** Stock down 10% YTD, it logged five straight years of gains till 2024

($1 = 86.6420 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Feb 21 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - RECEIVES WARNING LETTER FROM USFDA

• JAGSONPAL PHARMACEUTICALS LTD - USFDA CITES CGMP DEVIATION, REGISTRATION, AND LISTING VIOLATION

• JAGSONPAL PHARMACEUTICALS: USFDA WARNING REGARDING OBSERVATIONS DURING INSPECTION OF CONTRACT MANUFACTURING FACILITY OF JAGSONPAL

• JAGSONPAL PHARMACEUTICALS - FINANCIAL IMPACT INCLUDES SALE OF 35 MILLION RUPEES

Source text: ID:nBSEbDdYHY

Further company coverage: JGSN.NS

(([email protected];))

Feb 5 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• NAMES SACHIN JAIN AS CHIEF FINANCIAL OFFICER

Source text: [ID:]

Further company coverage: JGSN.NS

(([email protected];;))

** Jagsonpal Pharmaceuticals JGSN.NS jumps 7% to 244 rupees

** Co's Q3 profit jumps nearly three-fold, helped by strong sales of gynaecology products

** About 900,000 shares traded in stock's most active session since Dec. 3, 2024

** JGSN marginally up YTD; had risen 57% in 2024

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 22 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - CFO ASHISH LAKHOTIA RESIGNS

Source text: ID:nBSE5Z828b

Further company coverage: JGSN.NS

(([email protected];))

Nov 19 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - GOT 410 MILLION RUPEES TOWARDS SALE OF CO'S FARIDABAD FACILITY

Source text: ID:nNSE6311kK

Further company coverage: JGSN.NS

(([email protected];))

** Shares of Jagsonpal Pharmaceuticals Ltd JGSN.NS rise as much as 5.6% to 499.80 rupees

** Pharma co reported 53.4% y/y rise in Q2 profit to 114.6 mln rupees ($1.4 mln); rev jumped 29.2%

** Board also approved sub division of shares

** Stock on track to gain for 5th straight month; gained 18.3% so far this month

** More than 163,000 shares traded as of 10:13 a.m. IST, vs their 30-day moving avg of 89,502 shares

** JGSN last up 3.5%, adding to YTD gains of 26% so far

($1 = 84.0650 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Oct 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - APPROVED SUB-DIVISION OF SHARES

Source text for Eikon: ID:nBSE1mV11V

Further company coverage: JGSN.NS

(([email protected];))

May 24 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES MEMUP, A BIOIDENTICAL HORMONE REPLACEMENT THERAPY

Source text for Eikon: ID:nBSE7hQtsH

Further company coverage: JGSN.NS

(([email protected];))

March 8 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES QUEEZY-ER®

• QUEEZY-ER® PROVIDING RELIEF FROM NAUSEA AND VOMITING IN PREGNANCY

Source text for Eikon: [ID:]

Further company coverage: JGSN.NS

(([email protected];))

May 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• DIVIDEND OF 5 RUPEES PER SHARE

• MARCH-QUARTER NET PROFIT 56 MILLION RUPEES VERSUS PROFIT 3.1 MILLION RUPEES

• MARCH-QUARTER REVENUE FROM OPERATIONS 554.5 MILLION RUPEES VERSUS 512.3 MILLION RUPEES

Source text for Eikon: ID:nBSE7Q3W2k

Further company coverage: JGSN.NS

(([email protected];))